The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely to lose big time now that Donald Trump has been re-elected

KPTI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,457,465.35

Karyopharm Therapeutics Insider Trading History Chart

Karyopharm Therapeutics Share Price & Price History

^$0.85

▲ +0.07 (9.03%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Karyopharm Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/4/2024	Richard A Paulson	CEO	Sell	3,607	$0.88	$3,174.16	1,135,607
8/6/2024	Richard A Paulson	CEO	Sell	3,608	$0.93	$3,355.44	1,142,881
7/30/2024	Stuart Poulton	EVP	Sell	2,883	$1.06	$3,055.98	326,628
7/5/2024	Richard A Paulson	CEO	Sell	3,616	$0.85	$3,073.60	1,146,489
6/7/2024	Deepika Pakianathan	Director	Sell	231,548	$0.95	$219,970.60
6/5/2024	Deepika Pakianathan	Director	Sell	468,044	$0.96	$449,322.24	3,385
6/4/2024	Michael Mason	CFO	Sell	652	$0.99	$645.48	398,104
6/4/2024	Richard A Paulson	CEO	Sell	3,592	$0.99	$3,556.08	1,150,105
6/3/2024	Deepika Pakianathan	Director	Sell	360,744	$1.00	$360,744.00	11,209
5/31/2024	Deepika Pakianathan	Director	Sell	204,394	$0.95	$194,174.30	14,697
5/6/2024	Richard A Paulson	CEO	Sell	3,576	$1.13	$4,040.88	1,153,697
4/22/2024	Reshma Rangwala	EVP	Sell	6,789	$1.17	$7,943.13	342,931
4/4/2024	Richard A Paulson	CEO	Sell	3,563	$1.29	$4,596.27	1,157,273
3/5/2024	Richard A Paulson	CEO	Sell	3,573	$1.30	$4,644.90	1,160,836
2/29/2024	Michael Mano	SVP	Sell	16,973	$1.17	$19,858.41	281,428
2/29/2024	Michael Mason	CFO	Sell	27,687	$1.17	$32,393.79	404,918
2/29/2024	Reshma Rangwala	EVP	Sell	15,667	$1.17	$18,330.39	355,689
2/29/2024	Richard A Paulson	CEO	Sell	80,470	$1.17	$94,149.90	1,183,783
2/27/2024	Michael Mason	CFO	Sell	2,545	$1.32	$3,359.40	244,400
2/15/2024	Stuart Poulton	EVP	Sell	5,847	$1.33	$7,776.51	163,772
2/6/2024	Michael Mason	CFO	Sell	4,205	$1.59	$6,685.95	246,945
2/6/2024	Richard A Paulson	CEO	Sell	4,012	$1.59	$6,379.08	821,453
1/4/2024	Richard A Paulson	CEO	Sell	4,114	$0.82	$3,373.48	783,465
12/4/2023	Richard A Paulson	CEO	Sell	3,622	$0.79	$2,861.38	787,579
11/6/2023	Richard A Paulson	CEO	Sell	3,606	$0.92	$3,317.52	791,201
10/4/2023	Richard A Paulson	CEO	Sell	3,589	$1.27	$4,558.03	794,807
9/12/2023	Garen G. Bohlin	Director	Buy	41,140	$1.22	$50,190.80	45,140
9/1/2023	Michael Mano	SVP	Sell	3,888	$1.33	$5,171.04	142,234
9/1/2023	Michael Mason	CFO	Sell	6,913	$1.33	$9,194.29	237,817
9/1/2023	Sohanya Roshan Cheng	EVP	Sell	7,415	$1.33	$9,861.95	204,086
8/7/2023	Richard A Paulson	CEO	Sell	3,722	$1.72	$6,401.84	802,018
7/28/2023	Stuart Poulton	EVP	Sell	2,845	$1.70	$4,836.50	156,286
7/5/2023	Richard A Paulson	CEO	Sell	3,538	$1.72	$6,085.36	805,740
6/8/2023	Sohanya Roshan Cheng	EVP	Sell	1,839	$2.35	$4,321.65	211,501
5/4/2023	Richard A Paulson	CEO	Sell	3,805	$3.35	$12,746.75	812,814
4/20/2023	Reshma Rangwala	EVP	Sell	6,770	$4.05	$27,418.50	158,230
4/4/2023	Richard A Paulson	CEO	Sell	3,497	$3.97	$13,883.09	816,619
3/6/2023	Richard A Paulson	CEO	Sell	3,506	$3.16	$11,078.96	820,116
3/1/2023	Michael Mason	CFO	Sell	11,205	$3.03	$33,951.15	245,361
3/1/2023	Richard A Paulson	CEO	Sell	33,033	$3.03	$100,089.99	823,622
3/1/2023	Sohanya Roshan Cheng	EVP	Sell	11,239	$3.03	$34,054.17	210,687
3/1/2023	Stephen Mitchener	SVP	Sell	6,357	$3.03	$19,261.71	128,313
2/15/2023	Stuart Poulton	EVP	Sell	5,869	$3.19	$18,722.11	64,131
1/4/2023	Richard A Paulson	CEO	Sell	3,922	$3.27	$12,824.94	608,605
12/5/2022	Richard A Paulson	CEO	Sell	3,490	$5.17	$18,043.30	612,527
11/4/2022	Richard A Paulson	CEO	Sell	3,493	$4.54	$15,858.22	616,017
10/4/2022	Richard A Paulson	CEO	Sell	3,488	$5.87	$20,474.56	619,510
9/8/2022	Richard A Paulson	CEO	Sell	3,479	$5.23	$18,195.17	622,998
8/4/2022	Richard A Paulson	CEO	Sell	2,314	$4.48	$10,366.72	626,477
7/8/2022	Richard A Paulson	CEO	Sell	2,115	$5.18	$10,955.70	628,791
6/13/2022	Sohanya Roshan Cheng	Insider	Sell	1,551	$5.21	$8,080.71	89,949
6/10/2022	Deepika Pakianathan	Director	Sell	1,307	$6.00	$7,842.00	16,673
6/8/2022	Deepika Pakianathan	Director	Sell	325,977	$6.50	$2,118,850.50	18,731
6/7/2022	Richard A Paulson	CEO	Sell	2,542	$5.76	$14,641.92	630,906
6/3/2022	Michael Mason	CFO	Sell	601	$6.04	$3,630.04	138,509
2/7/2022	Jatin Shah	EVP	Sell	1,704	$9.86	$16,801.44
2/7/2022	Michael Kauffman	Director	Sell	6,764	$9.86	$66,693.04
2/7/2022	Michael Mason	CFO	Sell	3,947	$9.86	$38,917.42
2/7/2022	Sharon Shacham	Insider	Sell	6,707	$9.86	$66,131.02
12/2/2021	Stephen Mitchener	SVP	Sell	499	$6.69	$3,338.31

Bill Gates’ is about to mint millionaires (again) with Stargate.

From Brownstone Research | Ad

This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

SEC Filings (Institutional Ownership Changes) for Karyopharm Therapeutics (NASDAQ:KPTI)

66.44% of Karyopharm Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Karyopharm Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/19/2024	Barclays PLC	95,767	$79K	0.0%	-89.0%	0.076%
11/16/2024	Geode Capital Management LLC	1,355,392	$1.13M	0.0%	+3.3%	1.082%
11/15/2024	Barclays PLC	95,767	$79K	0.0%	-89.0%	0.076%
11/15/2024	Jane Street Group LLC	204,750	$0.17M	0.0%	-86.8%	0.163%
11/15/2024	State Street Corp	409,510	$0.34M	0.0%	-9.8%	0.327%
11/15/2024	Point72 Asia Singapore Pte. Ltd.	82,446	$68K	0.0%	-50.1%	0.066%
11/13/2024	BNP Paribas Financial Markets	1,982,354	$1.65M	0.0%	-12.8%	1.582%
11/13/2024	FMR LLC	369,723	$0.31M	0.0%	+26.1%	0.295%
11/5/2024	GSA Capital Partners LLP	1,775,700	$1.47M	0.1%	+80.6%	1.424%
10/10/2024	Exchange Traded Concepts LLC	218,791	$0.18M	0.0%	+34.9%	0.176%
9/16/2024	Point72 DIFC Ltd	35,939	$31K	0.0%	N/A	0.029%
9/16/2024	Cubist Systematic Strategies LLC	568,975	$0.49M	0.0%	N/A	0.456%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	165,318	$0.14M	0.0%	N/A	0.133%
8/15/2024	AQR Capital Management LLC	748,020	$0.65M	0.0%	+494.5%	0.600%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	165,318	$0.14M	0.0%	N/A	0.133%
8/14/2024	Cubist Systematic Strategies LLC	568,975	$0.49M	0.0%	N/A	0.457%
8/14/2024	Point72 DIFC Ltd	35,939	$31K	0.0%	N/A	0.029%
8/14/2024	Marshall Wace LLP	2,580,863	$2.25M	0.0%	-0.6%	2.071%
8/12/2024	XTX Topco Ltd	140,576	$0.12M	0.0%	-42.1%	0.113%
8/9/2024	Renaissance Technologies LLC	756,227	$0.66M	0.0%	-16.6%	0.607%
8/6/2024	Acadian Asset Management LLC	194,168	$0.17M	0.0%	N/A	0.156%
8/6/2024	Los Angeles Capital Management LLC	354,020	$0.31M	0.0%	-8.6%	0.284%
7/26/2024	Bank of New York Mellon Corp	166,315	$0.14M	0.0%	-65.9%	0.133%
5/17/2024	Ikarian Capital LLC	409,355	$0.62M	0.1%	+2.3%	0.348%
5/10/2024	Vanguard Group Inc.	8,338,401	$12.59M	0.0%	-4.3%	7.160%
5/3/2024	GSA Capital Partners LLP	1,299,151	$1.96M	0.2%	-44.4%	1.115%
4/24/2024	Simplicity Wealth LLC	44,011	$66K	0.0%	N/A	0.038%
2/15/2024	Birchview Capital LP	469,832	$0.41M	0.3%	-17.8%	0.410%
2/12/2024	Monashee Investment Management LLC	132,435	$0.12M	0.0%	N/A	0.116%
2/8/2024	Panagora Asset Management Inc.	227,445	$0.20M	0.0%	N/A	0.199%
2/7/2024	BNP Paribas Financial Markets	1,769,184	$1.53M	0.0%	+6.5%	1.545%
2/6/2024	Los Angeles Capital Management LLC	391,540	$0.34M	0.0%	N/A	0.342%
1/29/2024	Simplicity Solutions LLC	37,938	$33K	0.0%	N/A	0.033%
1/25/2024	Bleakley Financial Group LLC	37,938	$33K	0.0%	N/A	0.033%
1/12/2024	SG Americas Securities LLC	73,430	$64K	0.0%	+295.0%	0.064%
1/5/2024	Exchange Traded Concepts LLC	115,864	$100K	0.0%	+34.0%	0.101%
11/15/2023	Tejara Capital Ltd	1,077,388	$1.44M	0.8%	-5.8%	0.941%
11/15/2023	GSA Capital Partners LLP	568,298	$0.76M	0.1%	N/A	0.496%
11/14/2023	Avidity Partners Management LP	8,298,570	$11.12M	0.4%	-0.9%	7.246%
11/13/2023	Silverarc Capital Management LLC	561,955	$0.75M	0.2%	+8.3%	0.491%
11/13/2023	Tejara Capital Ltd	1,077,388	$1.44M	1.1%	-5.8%	0.941%
11/8/2023	Wade G W & Inc.	45,140	$60K	0.0%	N/A	0.039%
11/7/2023	Quantbot Technologies LP	21,699	$29K	0.0%	-60.1%	0.019%
11/7/2023	Barclays PLC	1,152,298	$1.54M	0.0%	+4.2%	1.008%
10/18/2023	Exchange Traded Concepts LLC	86,484	$0.12M	0.0%	+30.2%	0.076%
8/15/2023	Silverarc Capital Management LLC	518,985	$0.93M	0.3%	-66.3%	0.454%
8/14/2023	Prelude Capital Management LLC	15,933	$29K	0.0%	-62.4%	0.014%
8/14/2023	Graham Capital Management L.P.	62,414	$0.11M	0.0%	N/A	0.055%
8/11/2023	Rubric Capital Management LP	919,196	$1.65M	0.1%	-79.3%	0.804%
8/11/2023	Tejara Capital Ltd	1,143,991	$2.05M	1.0%	+128.1%	1.000%
8/11/2023	Platinum Investment Management Ltd.	500,000	$0.90M	0.0%	N/A	0.437%
8/11/2023	ExodusPoint Capital Management LP	2,382,451	$4.27M	0.0%	N/A	2.083%
8/9/2023	BNP Paribas Arbitrage SNC	461,096	$0.83M	0.0%	+24.8%	0.403%
8/8/2023	AlphaCentric Advisors LLC	810,000	$1.45M	0.8%	+237.5%	0.708%
8/8/2023	Candriam S.C.A.	1,435,694	$2.57M	0.0%	-6.5%	1.255%
8/7/2023	Principal Financial Group Inc.	32,838	$59K	0.0%	-32.8%	0.029%
8/7/2023	Acadian Asset Management LLC	98,946	$0.18M	0.0%	N/A	0.087%
8/4/2023	American International Group Inc.	54,514	$98K	0.0%	+45.1%	0.048%
7/26/2023	Simplicity Solutions LLC	15,966	$29K	0.0%	N/A	0.014%
7/20/2023	Exchange Traded Concepts LLC	66,422	$0.12M	0.0%	N/A	0.058%
7/19/2023	Kennedy Investment Group	35,000	$63K	0.0%	+75.0%	0.031%
7/10/2023	SG Americas Securities LLC	14,868	$27K	0.0%	-58.5%	0.013%
6/1/2023	Prelude Capital Management LLC	42,427	$0.17M	0.0%	-27.5%	0.037%
6/1/2023	Kennedy Investment Group	20,000	$78K	0.0%	N/A	0.018%
5/16/2023	Altium Capital Management LP	505,781	$1.97M	1.1%	N/A	0.444%
5/15/2023	Affinity Asset Advisors LLC	460,979	$1.79M	0.6%	-30.3%	0.404%
5/15/2023	Rubric Capital Management LP	4,441,056	$17.28M	0.4%	-46.5%	3.895%
5/12/2023	AlphaCentric Advisors LLC	240,000	$0.93M	0.6%	N/A	0.211%
5/12/2023	Profund Advisors LLC	167,517	$0.65M	0.0%	N/A	0.147%
5/11/2023	Citigroup Inc.	730,027	$2.84M	0.0%	+43.5%	0.640%
5/11/2023	E Fund Management Co. Ltd.	51,849	$0.20M	0.0%	+42.0%	0.045%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	187,450	$0.73M	0.0%	-56.6%	0.164%
5/9/2023	Russell Investments Group Ltd.	94,380	$0.37M	0.0%	-35.4%	0.083%
5/4/2023	Barclays PLC	2,847,389	$11.08M	0.0%	+172.0%	2.499%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	37,398	$0.15M	0.0%	N/A	0.033%
5/4/2023	Los Angeles Capital Management LLC	113,724	$0.44M	0.0%	+11.6%	0.100%
5/2/2023	Victory Capital Management Inc.	11,684	$45K	0.0%	N/A	0.010%
4/28/2023	SG Americas Securities LLC	35,864	$0.14M	0.0%	N/A	0.031%
4/27/2023	Arizona State Retirement System	31,090	$0.12M	0.0%	+53.4%	0.027%
4/20/2023	Hennion & Walsh Asset Management Inc.	139,574	$0.54M	0.0%	-3.3%	0.122%
4/20/2023	Banque Cantonale Vaudoise	15,000	$58K	0.0%	+175.2%	0.013%
3/23/2023	MetLife Investment Management LLC	29,394	$100K	0.0%	-29.0%	0.026%
2/15/2023	Armistice Capital LLC	3,853,565	$13.10M	0.2%	N/A	4.748%
2/15/2023	Avidity Partners Management LP	9,633,911	$32.76M	0.7%	N/A	11.871%
2/13/2023	ExodusPoint Capital Management LP	1,106,132	$3.76M	0.1%	+56.4%	1.363%
2/13/2023	Martingale Asset Management L P	45,315	$0.15M	0.0%	N/A	0.056%
2/13/2023	GSA Capital Partners LLP	82,162	$0.28M	0.0%	N/A	0.101%
2/10/2023	Opaleye Management Inc.	1,206,841	$4.28M	1.5%	N/A	1.487%
2/10/2023	New York Life Investment Management LLC	76,968	$0.26M	0.0%	+12.7%	0.095%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	432,278	$1.47M	0.0%	+178.1%	0.533%
2/10/2023	Moors & Cabot Inc.	12,200	$41K	0.0%	-42.3%	0.015%
2/9/2023	Principal Financial Group Inc.	56,805	$0.19M	0.0%	+186.5%	0.070%
2/9/2023	Monashee Investment Management LLC	481,696	$1.64M	0.7%	N/A	0.594%
2/9/2023	Citigroup Inc.	508,593	$1.73M	0.0%	-16.3%	0.627%
2/8/2023	UBS Group AG	523,259	$1.78M	0.0%	+364.9%	0.645%
2/8/2023	Swiss National Bank	259,150	$0.88M	0.0%	+52.9%	0.319%
2/8/2023	Russell Investments Group Ltd.	146,160	$0.50M	0.0%	+12.9%	0.180%
2/7/2023	State Board of Administration of Florida Retirement System	27,015	$92K	0.0%	-49.1%	0.033%
2/7/2023	Fox Run Management L.L.C.	28,823	$98K	0.0%	N/A	0.036%
2/6/2023	Los Angeles Capital Management LLC	101,917	$0.35M	0.0%	+29.6%	0.126%

Data available starting January 2016

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $0.85

$0.77

$0.87

50 Day Range

MA: $0.83

$0.70

$0.99

52 Week Range

Now: $0.85

$0.62

$1.95

Volume

518,398 shs

Average Volume

1,051,168 shs

Market Capitalization

$105.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16

Who are the company insiders with the largest holdings of Karyopharm Therapeutics?: Karyopharm Therapeutics' top insider shareholders include:
Richard A Paulson (CEO)
Michael Mason (CFO)
Reshma Rangwala (EVP)
Stuart Poulton (EVP)
Michael Mano (SVP)
Sohanya Roshan Cheng (EVP)
Stephen Mitchener (SVP)
Garen G Bohlin (Director)
Deepika Pakianathan (Director)
Learn More about top insider investors at Karyopharm Therapeutics.
Who are the major institutional investors of Karyopharm Therapeutics?: Karyopharm Therapeutics' top institutional shareholders include:
BNP Paribas Financial Markets — 1.58%
GSA Capital Partners LLP — 1.42%
Geode Capital Management LLC — 1.08%
State Street Corp — 0.33%
FMR LLC — 0.30%
Exchange Traded Concepts LLC — 0.18%
Learn More about top institutional investors of Karyopharm Therapeutics stock.
Which major investors are selling Karyopharm Therapeutics stock?: Within the previous quarter, KPTI stock was sold by these institutional investors:
Jane Street Group LLC
Barclays PLC
Barclays PLC
BNP Paribas Financial Markets
Point72 Asia Singapore Pte. Ltd.
State Street Corp
Within the last year, company insiders that have sold Karyopharm Therapeutics company stock include:
Richard A Paulson (CEO)
Michael Mason (CFO)
Reshma Rangwala (EVP)
Stuart Poulton (EVP)
Michael Mano (SVP)
Sohanya Roshan Cheng (EVP)
Learn More investors selling Karyopharm Therapeutics stock.
Which major investors are buying Karyopharm Therapeutics stock?: In the last quarter, KPTI stock was purchased by institutional investors including:
GSA Capital Partners LLP
FMR LLC
Exchange Traded Concepts LLC
Geode Capital Management LLC
Wolverine Trading LLC

From StockEarnings | Ad